拉昔布单抗。
Raxibacumab.
机构信息
Genetics Graduate Program, Department of Anatomy and Cell Biology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA.
出版信息
MAbs. 2009 Nov-Dec;1(6):531-8. doi: 10.4161/mabs.1.6.10195. Epub 2009 Nov 29.
Abstract
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen. HGS is currently providing stockpiles of the agent to the US government for use in the prevention and treatment of inhalation anthrax. As of May 2009, the candidate was undergoing review by the US Food and Drug Administration. The availability of bioterrorism countermeasures has become more important since the September 2001 anthrax attacks, and development of raxibacumab is a significant advance in this area.
摘要
里来霉素（ABthrax）是一种针对炭疽芽孢杆菌保护性抗原的人源 IgG1 单克隆抗体。HGS 目前正在向美国政府提供该药物的库存，用于预防和治疗吸入性炭疽病。截至 2009 年 5 月，该候选药物正在接受美国食品和药物管理局的审查。自 2001 年 9 月炭疽袭击事件以来，生物恐怖主义对策的可用性变得更加重要，而里来霉素的开发是这一领域的重大进展。
相似文献
1
Raxibacumab.拉昔布单抗。
MAbs. 2009 Nov-Dec;1(6):531-8. doi: 10.4161/mabs.1.6.10195. Epub 2009 Nov 29.
2
Monoclonal antibody therapies against anthrax.抗炭疽病的单克隆抗体疗法。
Toxins (Basel). 2011 Aug;3(8):1004-19. doi: 10.3390/toxins3081004. Epub 2011 Aug 15.
3
Passive Immunotherapy Protects against Enteric Invasion and Lethal Sepsis in a Murine Model of Gastrointestinal Anthrax.被动免疫疗法可保护小鼠胃肠道炭疽模型免受肠道侵袭和致死性败血症的侵害。
Toxins (Basel). 2015 Sep 29;7(10):3960-76. doi: 10.3390/toxins7103960.
4
Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.吸入炭疽孢子攻击未治疗或左氧氟沙星/raxibacumab 治疗的新西兰白兔中的炭疽杆菌保护性抗原动力学。
Toxins (Basel). 2013 Jan 14;5(1):120-38. doi: 10.3390/toxins5010120.
5
Raxibacumab for inhalational anthrax: an effective specific therapeutic approach?瑞昔巴库单抗治疗吸入性炭疽：一种有效的特效治疗方法？
Expert Opin Investig Drugs. 2010 Jul;19(7):909-11. doi: 10.1517/13543784.2010.489547.
6
Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax.治疗炭疽的治疗性抗体疗效存疑。
mSphere. 2019 Jun 19;4(3):e00282-19. doi: 10.1128/mSphere.00282-19.
7
Human-derived, plant-produced monoclonal antibody for the treatment of anthrax.用于治疗炭疽的人源化、植物生产的单克隆抗体。
Vaccine. 2005 Mar 18;23(17-18):2082-6. doi: 10.1016/j.vaccine.2005.01.013.
8
Tackling anthrax.应对炭疽病
Nature. 2001 Nov 8;414(6860):160-1. doi: 10.1038/35102660.
9
Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.抗炭疽致死因子和保护性抗原的人源单克隆抗体可独立发挥作用，预防炭疽杆菌感染，并增强机体对炭疽的内源性免疫力。
Infect Immun. 2007 Nov;75(11):5425-33. doi: 10.1128/IAI.00261-07. Epub 2007 Jul 23.
10
A therapeutic human antibody against the domain 4 of the Bacillus anthracis protective antigen shows protective efficacy in a mouse model.一种针对炭疽芽孢杆菌保护性抗原结构域 4 的治疗性人源抗体在小鼠模型中显示出保护效力。
Biochem Biophys Res Commun. 2019 Feb 5;509(2):611-616. doi: 10.1016/j.bbrc.2018.12.146. Epub 2018 Dec 31.
引用本文的文献
1
Phage Display as a Medium for Target Therapy Based Drug Discovery, Review and Update.基于噬菌体展示的靶向治疗药物发现：综述与更新
Mol Biotechnol. 2025 Jun;67(6):2161-2184. doi: 10.1007/s12033-024-01195-6. Epub 2024 Jun 1.
2
Development of a New Cell-Based AP-1 Gene Reporter Potency Assay for Anti-Anthrax Toxin Therapeutics.开发一种新的基于细胞的 AP-1 基因报告基因效力测定法，用于抗炭疽毒素治疗药物。
Toxins (Basel). 2023 Aug 28;15(9):528. doi: 10.3390/toxins15090528.
3
Clinical and Translational Pharmacology Considerations for Anti-infectives Approved Under the FDA Animal Rule.《FDA 动物法则批准的抗感染药物的临床与转化药理学考虑》
Clin Pharmacokinet. 2023 Jul;62(7):943-953. doi: 10.1007/s40262-023-01267-x. Epub 2023 Jun 16.
4
Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy.用于预防和治疗呼吸道合胞病毒、严重急性呼吸综合征冠状病毒 2 型、人类免疫缺陷病毒、狂犬病和细菌感染的单克隆抗体：来自世界传染病和免疫疾病协会以及意大利抗感染治疗学会的最新更新。
Front Immunol. 2023 May 15;14:1162342. doi: 10.3389/fimmu.2023.1162342. eCollection 2023.
5
Evolution of phage display libraries for therapeutic antibody discovery.噬菌体展示文库在治疗性抗体发现中的演变。
MAbs. 2023 Jan-Dec;15(1):2213793. doi: 10.1080/19420862.2023.2213793.
6
Recent Advances in Monoclonal Antibody-Based Approaches in the Management of Bacterial Sepsis.基于单克隆抗体的细菌脓毒症治疗方法的最新进展
Biomedicines. 2023 Mar 2;11(3):765. doi: 10.3390/biomedicines11030765.
7
Efficacy of ANTHRASIL (Anthrax Immune Globulin Intravenous (Human)) in rabbit and nonhuman primate models of inhalational anthrax: Data supporting approval under animal rule.炭疽免疫球蛋白静脉注射（人用）（ANTHRASIL）在兔和非人类灵长类动物吸入性炭疽模型中的疗效：支持根据动物规则批准的数据。
PLoS One. 2023 Mar 17;18(3):e0283164. doi: 10.1371/journal.pone.0283164. eCollection 2023.
8
Antimicrobial Resistance and Recent Alternatives to Antibiotics for the Control of Bacterial Pathogens with an Emphasis on Foodborne Pathogens.抗菌药物耐药性以及近期用于控制细菌病原体（重点是食源性病原体）的抗生素替代物
Antibiotics (Basel). 2023 Jan 30;12(2):274. doi: 10.3390/antibiotics12020274.
9
The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic.耐多药/广泛耐药革兰氏阴性呼吸道感染的威胁：另一场大流行。
Eur Respir Rev. 2022 Oct 19;31(166). doi: 10.1183/16000617.0068-2022. Print 2022 Dec 31.
10
Monoclonal Antibodies for Bacterial Pathogens: Mechanisms of Action and Engineering Approaches for Enhanced Effector Functions.用于细菌病原体的单克隆抗体：作用机制及增强效应功能的工程方法
Biomedicines. 2022 Aug 30;10(9):2126. doi: 10.3390/biomedicines10092126.
本文引用的文献
1
Protecting against future shock--inhalational anthrax.预防未来的冲击——吸入性炭疽
N Engl J Med. 2009 Jul 9;361(2):191-3. doi: 10.1056/NEJMe0903259.
2
Raxibacumab for the treatment of inhalational anthrax.瑞西巴库单抗用于治疗吸入性炭疽。
N Engl J Med. 2009 Jul 9;361(2):135-44. doi: 10.1056/NEJMoa0810603.
3
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.抗毒素抗体在吸入性炭疽预防和治疗中的应用
Future Microbiol. 2009 Feb;4(1):35-43. doi: 10.2217/17460913.4.1.35.
4
Project BioShield: what it is, why it is needed, and its accomplishments so far.生物盾牌计划：是什么、为何需要以及迄今为止所取得的成就。
Clin Infect Dis. 2007 Jul 15;45 Suppl 1:S68-72. doi: 10.1086/518151.
5
Anti-infective monoclonal antibodies: perils and promise of development.抗感染单克隆抗体：开发中的风险与前景
Nat Rev Drug Discov. 2006 Mar;5(3):191-5. doi: 10.1038/nrd1987.
6
A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.在健康志愿者中开展的一项关于PAmAb（一种抗炭疽杆菌保护性抗原的全人单克隆抗体）的1期研究。
Clin Infect Dis. 2005 Jul 1;41(1):12-20. doi: 10.1086/430708. Epub 2005 May 24.
7
Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis.在炭疽败血症致死性毒素注入大鼠模型中，用保护性抗原导向单克隆抗体进行晚期治疗可改善血流动力学功能并提高生存率。
J Infect Dis. 2005 Feb 1;191(3):422-34. doi: 10.1086/427189. Epub 2004 Dec 22.
8
9
Anthrax as a biological weapon, 2002: updated recommendations for management.2002年炭疽作为生物武器：管理的最新建议
JAMA. 2002 May 1;287(17):2236-52. doi: 10.1001/jama.287.17.2236.
Zotero 插件